SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy

被引：12
|
作者：
Hope, Thomas A. [1 ]
Antonarakis, Emmanuel S. [2 ]
Bodei, Lisa [3 ]
Calais, Jeremie [4 ]
Iravani, Amir [5 ]
Jacene, Heather [6 ,7 ]
Koo, Phillip J. [8 ]
Morgans, Alicia K. [9 ]
Osborne, Joseph R. [10 ]
Tagawa, Scott T. [11 ]
Taplin, Mary-Ellen [9 ]
Sartor, Oliver [12 ]
Morris, Michael J. [13 ]
机构：
[1] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA
[2] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN USA
[3] Mem Sloan Kettering Canc Ctr, Dept Radiol, Mol Imaging & Therapy Serv, New York, NY USA
[4] UCLA, David Geffen Sch Med, Dept Mol & Med Pharmacol, Ahmanson Translat Theranost Div, Los Angeles, CA USA
[5] Univ Washington, Dept Radiol, Seattle, WA 98195 USA
[6] Brigham & Womens Hosp, Dept Radiol, Boston, MA USA
[7] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA
[8] Banner MD Anderson Canc Ctr, Phoenix, AZ USA
[9] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
[10] Weill Cornell Med, Mol Imaging & Therapeut, Dept Radiol, New York, NY USA
[11] Weill Cornell Med Coll, Dept Med, New York, NY USA
[12] Mayo Clin, Rochester, MN USA
[13] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, New York, NY USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2023年 / 64卷 / 09期
关键词：
RESISTANT PROSTATE-CANCER; SURVIVAL; CABAZITAXEL; SAFETY;
D O I：
10.2967/jnumed.123.265952
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Prostate-specific membrane antigen (PSMA) is a transmem-brane carboxypeptidase that is highly expressed in prostate cancer. Radioligand therapy (RLT) with 177Lu-labeled compounds has shown clinical benefit, and the U.S. Food and Drug Administration (FDA) approved 177Lu-PSMA-617 (177Lu-vipivotide tetraxetan [Pluvicto; Novartis]) for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) after progressing on taxane-based chemotherapy and at least 1 line of androgen recep-tor pathway inhibitors (ARPIs). This document aims to provide standardized guidance through expert consensus for the selection and management of patients being treated with 177Lu-PSMA RLT.
引用
收藏
页码：1417 / 1423
页数：7
相关论文
共 50 条
  • [31] [177Lu]PSMA-617 radionuclide therapy shows promise
    Conor A. Bradley
    Nature Reviews Urology, 2018, 15 : 468 - 468
  • [32] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response Reply
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Tripathi, Madhavi
    Bal, Chandrasekhal
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 168 - 169
  • [33] 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
    Kambiz Rahbar
    Hojjat Ahmadzadehfar
    Martin Boegemann
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 513 - 514
  • [34] 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Boegemann, Martin
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (03) : 513 - 514
  • [35] 177Lu-PSMA-617 therapy in Chemotherapy Naive patients: A single center experience
    Kulkarni, Raksha
    Abdelrahman, Ahmed
    Novello, Matteo
    Cengiz, Turgut Bora
    Akinlusi, Rahman
    Bander, Ilda
    Patel, Vaibhav
    Wise, David
    Ghesani, Munir
    Ghesani, Nasrin
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [36] First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands
    van Kalmthout, Ludwike
    Braat, Arthur
    Lam, Marnix
    van Leeuwaarde, Rachel
    Krijger, Gerard
    Ververs, Tessa
    Mehra, Niven
    Bins, Adriaan
    Hunting, Jarmo
    de Keizer, Bart
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (06) : 446 - 451
  • [37] Prognostic value of baseline imaging parameters prior to therapy with 177Lu-PSMA-617
    Ferdinandus, Justin
    Thang, Sue Ping
    Violet, John
    Hicks, Rodney
    Sandhu, Shahneen
    Hofman, Michael
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [38] Management of Dry Mouth Toxicity Following 177Lu-PSMA-617 Radioligand Therapy
    Pepin, Abigail
    Kiess, Ana
    Lukens, J. Nicholas
    Mulugeta, Philipose
    Taunk, Neil K.
    PRACTICAL RADIATION ONCOLOGY, 2025, 15 (01) : 14 - 18
  • [39] Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA617 in combination with ipilimumab and nivolumab for men with metastatic castrationresistant prostate cancer (mCRPC; ANZUP 2001).
    Sandhu, Shahneen
    Subramaniam, Shalini
    Hofman, Michael S.
    Stockler, Martin R.
    Martin, Andrew James
    Pokorski, Izabella
    Goh, Jeffrey C.
    Pattison, David A.
    Dhiantravan, Nattakorn
    Gedye, Craig
    Rutherford, Natalie K.
    Joshua, Anthony M.
    Tan, Thean Hsiang
    Kirkwood, Ian D.
    Weickhardt, Andrew James
    Lee, Sze Ting
    Alipour, Ramin
    Nguyen, Andrew
    Davis, Ian D.
    Emmett, Louise
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [40] Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)
    Pathmanandavel, Sarennya
    Crumbaker, Megan
    Ho, Bao
    Yam, Andrew O.
    Wilson, Peter
    Niman, Remy
    Ayers, Maria
    Sharma, Shikha
    Hickey, Adam
    Eu, Peter
    Stockler, Martin
    Martin, Andrew J.
    Joshua, Anthony M.
    Nguyen, Andrew
    Emmett, Louise
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (02) : 221 - 226
12345